Literature DB >> 2142565

Antagonistic effect of naloxone on the hypertensive response of intraventricularly administered histamine.

M S Młynarska1.   

Abstract

Intracerebroventricular (i.c.v.) injections of histamine (HA) to Vetbutal-anaesthetized rats elicited a biphasic pressure response: a fall of blood pressure (BP) in the first minute, followed by a rise in BP. The heart rate (HR) response was also biphasic: bradycardia in the first minute, followed by tachycardia. The H1-receptor agonist 2-pyridylethylamine (PEA) increased the fall in BP in the first minute in comparison with the HA group, and then elicited a rise in BP that was, however, much lower than that produced by HA. Throughout the experiment PEA produced essentially only a bradycardia. The H2-receptor agonist dimaprit elicited a single-phase pressor response, i.e. a rise in BP and did not elicit tachycardia. Intraventricular pretreatment of rats with naloxone greatly reduced the initial response (phase 1) in the first minute in HA groups by 77-83% and PEA groups by 83-100%. Naloxone given in small doses also reduced the fall in HR by 71-100% in those groups. The experimental results permit a conclusion that the phase 1 response, i.e. the fall in BP, results from excitation of H1-receptors. Thus we may propose that H1-receptors are involved in the action of naloxone. Naloxone in a dose of 0.1 microgram inhibited the hypertensive responses of HA after 25-30 min. The reduction reached 71%. Naloxone reduced the small rise in BP induced by PEA (10 micrograms) but totally blocked the rise in BP induced by dimaprit (50 micrograms). This blockade indicates that the central opioid system may transmit the total stimulating response (rise in BP) of H2 receptors induced by dimaprit. Participation of central opioid receptors in HA-stimulated responses has already been demonstrated in corticosterone secretion.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2142565     DOI: 10.1007/bf01969045

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  9 in total

1.  Central cardiovascular actions of histamine in rats: involvement of histamine H2-receptors.

Authors:  P E Hicks
Journal:  Clin Exp Hypertens       Date:  1978       Impact factor: 1.749

2.  The cardiovascular effects of intraventricularly administered histamine in the anaesthetised rat.

Authors:  L Finch; P E Hicks
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976-05       Impact factor: 3.000

3.  Cardiovascular and antidiuretic effects of central histamine.

Authors:  W E Hoffman; P G Schmid
Journal:  Life Sci       Date:  1978-05-15       Impact factor: 5.037

4.  Action of histamine and H1 and H2 blockers on the cardiopulmonary circulation.

Authors:  J R Woods; C R Brinkman; A Dandavino; K Murayama; N S Assali
Journal:  Am J Physiol       Date:  1977-01

5.  The effect of a vasopressin antagonist on the pressor response to histamine administered centrally.

Authors:  P J Gatti; S B Gertner
Journal:  Neuropharmacology       Date:  1983-07       Impact factor: 5.250

6.  Studies on the mechanism of the cardiovascular action of central injections of histamine.

Authors:  M C Klein; S B Gertner
Journal:  Neuropharmacology       Date:  1983-09       Impact factor: 5.250

7.  Naloxone antagonizes a central histaminergic stimulation of corticosterone secretion in rats.

Authors:  A Gadek-Michalska; J Bugajski
Journal:  Agents Actions       Date:  1988-04

8.  Mu-receptors mediate opioid cardiovascular effects at anterior hypothalamic sites through sympatho-adrenomedullary and parasympathetic pathways.

Authors:  A Pfeiffer; G Feuerstein; R L Zerbe; A I Faden; I J Kopin
Journal:  Endocrinology       Date:  1983-09       Impact factor: 4.736

9.  Evidence for a role of endogenous histamine in central cardiovascular regulation: inhibition of histamine-N-methyltransferase by SKF 91488.

Authors:  M C Klein; S B Gertner
Journal:  J Pharmacol Exp Ther       Date:  1981-02       Impact factor: 4.030

  9 in total
  1 in total

1.  Interaction between the central histaminergic and the muscarinic cholinergic systems.

Authors:  M S Młynarska
Journal:  Agents Actions       Date:  1994-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.